Idenix Inks HIV-Drug Deal With GSK Worth Up to $450 Million

Shares of Idenix Pharmaceuticals jumped in pre-market trading on the news that the Cambridge, MA-based developer of treatments for infectious diseases has inked a deal with pharma giant GlaxoSmithKline potentially worth some $450 million.
Xconomy